Why Are Tandem Diabetes Shares Falling Premarket Today?

  • Tandem Diabetes Care Inc TNDM reported Q3 sales of $179.6 million, +45% Y/Y, beating the consensus of $171.41 million.
  • The Company posted EPS of $0.09, a turnaround from a loss of $(0.15) and beating the Wall Street estimate of $0.06.
  • Worldwide pump shipments increased 43% Y/Y to 31,558 pumps, but lower than 33,817 reported in Q2 FY21.
  • Gross margin improved to 54% from 53%, and operating margin improved to 4% from negative 1%.
  • Domestic pump shipments increased 10% to 20,296 pumps, slightly above 20,665 in Q2 FY21. Domestic sales were $133.1 million, +24%. 
  • International pump shipments increased to 11,262 pumps, but lower than 13,152 in Q2 of FY21. International sales increased 189% to $46.5 million.
  • Tandem Diabetes ended Q3 with cash, cash equivalents, and short-term investments of $595.0 million.
  • Guidance: Tandem forecasts sales of $685 million - $695 million (consensus of $684.32 million), compared to prior guidance of $670 million - $685 million.
  • The Company sees International sales of approximately $168 million - $173 million, higher than prior guidance of $160 million - $165 million.
  • Price Action: TNDM shares are trading lower by 10.2% at $127.01 premarket on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!